Quantitative mRNA expression analysis of neurotrophin-receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples

Neuropathology

Volumn 26, Issue 5, 2006, Pages 393-399

  Kunz, Franzisca ^a   Shalaby, Tarek ^a   Lang, Doris ^a   Von Büren, André ^a   Hainfellner, Johannes A ^c   Slavc, Irene ^d   Tabatabai, Ghazaleh ^b,e   Grotzer, Michael A ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ST ANNA CHILDREN S HOSPITAL   (Austria)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Brain tumor; c MYC; Medulloblastoma; Primitive neuroectodermal tumor; Prognosis; TrkC

Indexed keywords

FORMALDEHYDE; MESSENGER RNA; MYC PROTEIN; NEUROTROPHIN RECEPTOR; TUMOR MARKER; TYROSINE KINASE C; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NEUROECTODERM TUMOR; ONCOGENE C MYC; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTO ONCOGENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA DEGRADATION; RNA ISOLATION; TISSUE SECTION;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FORMALDEHYDE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; INFANT; NEUROECTODERMAL TUMORS, PRIMITIVE; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, TRKC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE FIXATION;

EID: 33749002833     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2006.00694.x     Document Type: Article

References (35)

1. Gurney JG, Smith MA, Bunin GR.CNS and Miscellaneous Intracranial and Intraspinal Neoplasms. SEER Pediatric Monograph. [Cited 1999] National Cancer Institute, 2000; 51-63. Available from URL: http://seer.cancer.gov/publications/
2. Jenkin D. The radiation treatment of medulloblastoma. J Neurooncol 1996; 29: 45-54.
3. Rorke LB, Trojanowski JQ, Lee VM et al. Primitive neuroectodermal tumors of the central nervous system. Brain Pathol 1997; 7: 765-784.
4. Silber JH, Radcliffe J, Peckham V et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol 1992; 10: 1390-1396.
5. Olshan JS, Gubernick J, Packer R et al. The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 1992; 70: 2013-2017.
6. Radcliffe J, Packer RJ, Atkins TE et al. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol 1992; 32: 551-554.
7. Chapman CA, Waber DP, Bernstein JH et al. Neurobehavioral and neurologic outcome in long term survivors of posterior fossa brain tumors: role of age and perioperative factors. J Child Neurol 1995; 10: 209-212.
8. Dennis M, Spiegler BJ, Hetherington CR, Greenberg ML. Neuropsychological sequelae of the treatment of children with medulloblastoma. J Neurooncol 1996; 29: 91-101.
9. Garton GR, Schomberg PJ, Scheithauer BW et al. Medulloblastoma - prognostic factors and outcome of treatment: review of the Mayo clinic experience. Mayo Clin Proc 1990; 65: 1077-1086.
10. Kopelson G, Linggood RM, Kleinman GM. Medulloblastoma. The identification of prognostic subgroups and implications for multimodality management. Cancer 1983; 51: 312-319.
11. Albright AL, Wisoff JH, Zeltzer PM et al. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery 1996; 38: 265-271.
12. Tait DM, Thornton-Jones H, Bloom HJ et al. Adjuvant chemotherapy for medulloblastoma: the first multicentre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990; 26: 464-469.
13. Zeltzer PM, Boyett JM, Finlay JL et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999; 17: 832-845.
14. Kim JY, Sutton ME, Lu DJ et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999; 59: 711-719.
15. Grotzer MA, Janss AJ, Fung K-M et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000; 18: 1027-1035.
16. Grotzer MA, Hogarty MD, Janss AJ et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001; 7: 2425-2433.
17. Herms J, Neidt I, Lüscher B et al. C-myc expression in medulloblastoma and its prognostic value. Int J Cancer 2000; 89: 395-402.
18. Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415: 436-442.
19. Neben K, Korshunov A, Benner A et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 2004; 64: 3103-3111.
20. Eberhart CG, Kratz J, Wang Y et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004; 63: 441-449.
21. Fisher PG, Burger PC, Eberhart CG. Biologic risk stratification of medulloblastoma: the real time is now. J Clin Oncol 2004; 22: 971-974.
22. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25: 169-193.
23. Giulietti A, Overbergh L, Valckx D et al. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001; 25: 386-401.
24. Lahr G. RT-PCR from archival single cells is a suitable method to analyze specific gene expression. Lab Invest 2000; 80: 1477-1479.
25. Krafft AE, Duncan BW, Bijwaard KE et al. Optimization of the isolation and amplification of RNA from formalin-fixed, paraffin-embedded tissue: the armed forces institute of pathology experience and literature review. Mol Diagn 1997; 2: 217-230.
26. Lewis F, Maughan NJ, Smith V et al. Unlocking the archive - gene expression in paraffin-embedded tissue. J Pathol 2001; 195: 66-71.
27. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002; 29: 23-39.
28. Grotzer MA, Patti R, Geoerger B et al. Biological stability of RNA isolated from RNAlater - treated brain tumor and neuroblastoma xenografts. Med Pediatr Oncol 2000; 34: 438-442.
29. Zuzak TJ, Steinhoff DF, Sutton LN et al. Loss of caspase-8 gene expression is common in childhood primitive neuroectodermal braintumor/ medulloblastoma. Eur J Cancer 2002; 38: 92-98.
30. Bieche I, Nogues C, Paradis V et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 6: 452-459.
31. Klimecki WT, Futscher BW, Dalton WS. Effects of ethanol and paraformaldehyde on RNA yield and quality. Biotechniques 1994; 16: 1021-1023.
32. Specht K, Richter T, Muller U et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001; 158: 419-429.
33. Antonov J, Goldstein DR, Oberli A et al. Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. Lab Invest 2005; 85: 1040-1050.
34. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986-994.
35. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001; 25: 409-418.